An­a­lyz­ing the End­points 100; ‘Most fa­vored na­tion’ tar­gets re­vealed; Biotech slump makes leas­es a li­a­bil­i­ty; and ...

23 hours ago
Weekly

About 5% of CBER and CDER left af­ter FDA staff cuts, analy­sis finds

Yesterday
People
FDA+

Trump asks 'very tough hom­bre' Dr. Oz to lead MFN talks

Yesterday
Pharma

US warns drug­mak­ers against mis­rep­re­sent­ing cost of im­port­ed prod­ucts

Yesterday
Pharma
Law

CHMP clears path for GSK’s Blenrep re­launch, rec­om­mends four oth­er drugs 

Yesterday
Pharma
FDA+

Ku­ra spells out piv­otal AML tri­al win as it gears up to com­pete with Syn­dax

Yesterday
R&D

GLP-1s may cut can­cer risk; Gyre’s stock falls af­ter hep B da­ta and of­fer­ing

Yesterday
News Briefing

Fed­er­al judge ex­tends or­der block­ing RFK Jr. from re­or­ga­niz­ing HHS

Yesterday
FDA+
Law

Gilead notch­es an­oth­er Phase 3 win for Trodelvy in triple-neg­a­tive breast can­cer

Yesterday
R&D
Pharma

Ge­of­frey Porges ex­its Schrödinger with CFO swap; A new board seat for As­traZeneca's Pas­cal So­ri­ot

Yesterday
Peer Review

Volas­tra un­veils first hu­man da­ta of its sol­id tu­mor drug tar­get

2 days ago
R&D

Merus’ Phase 2 over­all sur­vival da­ta reach ‘home run’ sce­nario — an­a­lyst

2 days ago
R&D

GSK’s Nu­cala wins COPD ap­proval, stok­ing ri­val­ry with Dupix­ent 

2 days ago
Pharma
FDA+

Roche con­firms over­all sur­vival ben­e­fit for PI3K in­hibitor in breast can­cer

2 days ago
R&D
Pharma

Jazz out­lines full sur­vival da­ta for lung can­cer drug Zepzel­ca

2 days ago
R&D
Pharma

Up­dat­ed: FDA ex­pects 'time­ly avail­abil­i­ty' of Covid shots as ad­vi­sors up­date for­mu­la rec­om­men­da­tion

2 days ago
FDA+
Coronavirus

House pass­es Trump tax bill with PBM and or­phan drug re­forms in­clud­ed

2 days ago
Pharma
Law

FDA chief to sen­a­tors: 3,000+ staff de­par­tures won't de­lay user fee tar­gets

2 days ago
FDA+

Up­dat­ed: Hinge Health jumped 18% on its first day as the dig­i­tal health IPO mar­ket reawak­ens

2 days ago
Financing
Deals

Cigna, No­vo of­fer low­er GLP-1 prices to lure pa­tients to brand-name drugs

2 days ago
Pharma
Health Tech

FDA names act­ing head of in­spec­tions; J&J again ad­vo­cates for tax poli­cies as al­ter­na­tive to tar­iffs

2 days ago
Manufacturing

The ‘MA­HA re­port’: Four key take­aways on vac­cines, med­i­cine and the phar­ma in­dus­try

2 days ago
Pharma
FDA+

Meet the ‘first sale’ rule: A cus­toms loop­hole phar­ma com­pa­nies could use to ease tar­iff im­pact

2 days ago
Pharma
Manufacturing

An un­pre­dictable year for health­care

2 days ago
Health Tech
1234 Next page Last page
A service from the Financial Times